

**Complete Accounts of Integrated Drug Discovery and
Development: Recent Examples from the
Pharmaceutical Industry
Volume 5**

Printed from e-media with permission by:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571

Email: curran@proceedings.com
Web: www.proceedings.com



The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984. | ISBN 9798331320485 (pod)

Copyright © 2025 American Chemical Society

All Rights Reserved. Reprographic copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Act is allowed for internal use only, provided that a per-chapter fee of \$40.25 plus \$0.75 per page is paid to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. Republication or reproduction for sale of pages in this book is permitted only under license from ACS. Direct these and other permission requests to ACS Copyright Office, Publications Division, 1155 16th Street, N.W., Washington, DC 20036.

The citation of trade names and/or names of manufacturers in this publication is not to be construed as an endorsement or as approval by ACS of the commercial products or services referenced herein; nor should the mere reference herein to any drawing, specification, chemical process, or other data be regarded as a license or as a conveyance of any right or permission to the holder, reader, or any other person or corporation, to manufacture, reproduce, use, or sell any patented invention or copyrighted work that may in any way be related thereto. Registered names, trademarks, etc., used in this publication, even without specific indication thereof, are not to be considered unprotected by law.

PRINTED IN THE UNITED STATES OF AMERICA

Contents

Preface	ix
1. The Discovery and Chemical Development of Odalasvir, a Potent and Selective HCV NS5A Inhibitor	1
Duc N. Tran, Vittorio Farina, Alexander Zhdanko, Venkat R. Gadhachanda, Akihiro Hashimoto, Mingjun Huang, and Jason A. Wiles	
2. Discovery and Chemical Development of BI 1181181 MZ: A Bis-Spirocyclic BACE-1 Inhibitor for the Treatment of Alzheimer's Disease	59
Shankar Venkatraman and Jonathan T. Reeves	
3. Discovery and Early Process Development of a Selective and Orally Bioavailable VHL-Recruiting PROTAC Showing SMARCA2 Degradation In Vivo	97
Christiane Kofink, Peter Greb, Harald Weinstabl, and Jonathan T. Reeves	
4. Discovery and Development of Deucravacitinib (BMS-986165), a Small Molecule TYK2 Inhibitor for the Treatment of Autoimmune Diseases	137
Stephen T. Wroblewski, Daniel S. Treitler, and Eric M. Simmons	
5. Discovery and Process Development of a Novel Auristatin Drug-Linker: PF-08081016.....	197
Philip Moquist, Nicole Eng-Duncan, Svetlana Doronina, and Aaron Whittaker	
6. Gefapixant Citrate (MK-7264): Development of a Green Manufacturing Process	227
Douglas A. L. Otte and Hong Ren	
7. Making Anti-Tuberculosis Drug Bedaquiline Affordable by Tackling Low-Yielding Key Steps.....	281
Juliana M. S. Robey and Kai O. Donsbach	
8. Discovery and Development of Laquinimod: An Immunomodulator for Treatment of Multiple Sclerosis.....	311
Johan Wennerberg	
Editors' Biographies	333

Indexes

Author Index.....	337
Subject Index	339